

# **Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/GAEB7840DC37EN.html>

Date: September 2022

Pages: 89

Price: US\$ 3,500.00 (Single User License)

ID: GAEB7840DC37EN

## **Abstracts**

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Glycogen synthase kinase 3 beta also known as GSK3B is an enzyme encoded by the GSK3B. It constitutively activate protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules. It mediates the development of insulin resistance by regulating activation of transcription factors. It regulates protein synthesis by controlling the activity of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as glycogen synthase. It plays an important role in ERBB2-dependent stabilization of microtubules at the cell cortex. It phosphorylates MACF1, inhibiting its binding to microtubules which is critical for its role in bulge stem cell migration and skin wound repair. It regulates the circadian clock via phosphorylation of the major clock components including ARNTL/BMAL1, CLOCK and PER2.

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) pipeline Target constitutes close to 25 molecules. Out of which approximately 17 molecules are developed by companies and remaining by

the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 8 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 4 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Genetic Disorders, Musculoskeletal Disorders, Ear Nose Throat Disorders, Ophthalmology and Undisclosed which include indications Alzheimer's Disease, Lung Cancer, Pancreatic Cancer, Breast Cancer, Dementia Associated With Alzheimer's Disease, Ovarian Cancer, Tauopathies, Acute Sensorineural Hearing Loss, Adenoid Cystic Carcinoma (ACC), Amyotrophic Lateral Sclerosis, Angiosarcoma, Bipolar Disorder (Manic Depression), Bone Disorders, Bone Fracture, Bone Sarcoma, Central Nervous System (CNS) Tumor, Cognitive Impairment, Ependymoma, Esophageal Cancer, Ewing Sarcoma, Frontotemporal Dementia (FTD), Glioblastoma Multiforme (GBM), Hearing Disorders, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liposarcoma, Liver Cancer, Lymphoma, Major Depressive Disorder, Menkes Disease (Kinky Hair Disease), Metastatic Lung Cancer, Metastatic Melanoma, Metastatic Pancreatic Cancer, Multiple Sclerosis, Myelofibrosis, Myotonic Dystrophy, Neuroblastoma, Neurodegenerative Diseases, Osteogenesis Imperfecta, Osteosarcoma, Pancreatic Ductal Adenocarcinoma, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Post-Traumatic Stress Disorder (PTSD), Prostate Cancer, Retinitis Pigmentosa (Retinitis), Rhabdomyosarcoma, Salivary Gland Cancer, Sarcomas, Soft Tissue Sarcoma, Solid Tumor, Synovial Sarcoma, T-Cell Leukemia, Tay-Sachs Disease, Unspecified and Unspecified Central Nervous System Disorders.

The latest report Glycogen Synthase Kinase 3 Beta - Drugs In Development, 2022, outlays comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based

on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1)

The report reviews Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to

formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Overview

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Drug Profiles

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Dormant Products

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Discontinued Products

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases

Sep 21, 2022: IGC announces issuance of second patent for the treatment of Alzheimer's Using THC

Sep 16, 2022: Quince Therapeutics presents preclinical data at MHSRS 2022 demonstrating preclinical efficacy of bone-targeting platform for traumatic bone injury

Sep 12, 2022: Quince Therapeutics presents preclinical data at ASBMR 2022 demonstrating application of bone-targeting platform for spinal fusion and bone cancer indications

Aug 30, 2022: Quince Therapeutics presents preclinical data at OI 2022 demonstrating potential of a targeted anabolic for accelerated bone healing of osteogenesis imperfecta fractures

Jul 18, 2022: Alzamend Neuro receives positive pre-IND response from FDA for AL001 treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder

Jun 03, 2022: Innovative hearing restoration trial launches at the Medical College of Wisconsin

May 17, 2022: Alzamend Neuro announces pre-IND submission for AL001 as a treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder

May 05, 2022: Alzamend Neuro announces initiation of phase IIA multiple ascending dose clinical trial for AL001 treatment of dementia related to Alzheimer's

Apr 11, 2022: Alzamend Neuro contracts with Altasciences and iResearch Atlanta to manage and conduct its phase IIA study in patients with Alzheimer's

Mar 28, 2022: Actuate Therapeutics announces poster presentations at the 2022 AACR Annual Meeting

Mar 28, 2022: Alzamend Neuro announces full data set from phase 1 first-in-human clinical trial for AL001 treatment of Dementia Related to Alzheimer's

Mar 11, 2022: ENTA conducting clinical trial of investigational regenerative medication to restore hearing function in sensorineural hearing loss (SNHL) patients

Mar 01, 2022: Actuate Therapeutics announces first patient enrolled in Phase 2 clinical trial of elraglusib plus retifanlimab as investigational first line therapy for patients with advanced pancreatic cancer

Feb 07, 2022: Actuate Therapeutics announces initiation of a multicenter randomized trial of elraglusib plus FOLFIRINOX as first line therapy for advanced pancreatic cancer

Dec 22, 2021: AMO Pharma announces expansion of pivotal REACH-CDM study in congenital myotonic dystrophy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022  
Number of Products under Development by Therapy Areas, 2022  
Number of Products under Development by Indications, 2022  
Number of Products under Development by Indications, 2022 (Contd..1)  
Number of Products under Development by Indications, 2022 (Contd..2)  
Number of Products under Development by Companies, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Companies, 2022 (Contd..2)  
Products under Development by Companies, 2022 (Contd..3)  
Number of Products under Investigation by Universities/Institutes, 2022  
Products under Investigation by Universities/Institutes, 2022  
Number of Products by Stage and Mechanism of Actions, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Dormant Products, 2022  
Dormant Products, 2022 (Contd..1)  
Dormant Products, 2022 (Contd..2)  
Discontinued Products, 2022



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022  
Number of Products under Development by Therapy Areas, 2022  
Number of Products under Development by Top 10 Indications, 2022  
Number of Products by Mechanism of Actions, 2022  
Number of Products by Stage and Mechanism of Actions, 2022  
Number of Products by Top 10 Routes of Administration, 2022  
Number of Products by Stage and Top 10 Routes of Administration, 2022  
Number of Products by Top 10 Molecule Types, 2022  
Number of Products by Stage and Top 10 Molecule Types, 2022



## I would like to order

Product name: Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/GAEB7840DC37EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GAEB7840DC37EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970